because RAC have 128 million SOI (shares) we have ~5 billion now. I don’t know what there is not to understand, movement on IMU up 100% recently, is very significant.
So is this: FA stuff Keytruda trial, for Oesophageal Ca or GEJ.
https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-reduced-risk-of-death-by-27-versus-chemotherapy-as-first-line-treatment-for-locally-advanced-or-metastatic-esophageal-cancer/While Oesophageal cancer is really difficult to treat as is GEJ, this indication (GEJ) so gastro-oesophageal junction, was included in the IMU Her-Vaxx trial for Gastric cancer/ GEJ, so our numbers are really good, even up against Keytruda & look at the toxicity & drop out numbers also due to SAEs & toxicity.
Thanks
@The Captain, looking at numbers in the same way. It’s really phenomenal in the Oncology Immunotherapy space to get these kind of results & be awarded the kind of positive recognition we have by the DMSI or DSMB as it is known here.
Independent unlock of data, & LC has said only 5 more patients were required to trigger things anyway on the trial. These participants in India, Asia & Central Europe do not have access to drugs like Herceptin, just think yourself lucky if in Australia & you get sick. A whole lot more available on Medicare or clinical trials. As gastric cancers are more common in Asia (and possibly that may be due to a prevalent rate of Helico Bacter Pylori, another Australian first in research).
HAGWE all
